Testing a model of signals in the IPO offer process

被引：0
|
作者：
David R. Williams
W. Jack Duncan
Peter M. Ginter
机构：
[1] Appalachian State University,Health Care Management Program, John A. Walker College of Business
[2] University of Alabama at Birmingham,Graduate School of Management
[3] University of Alabama at Birmingham,School of Public Health
来源：
Small Business Economics | 2010年 / 34卷
关键词：
Signals; Initial public offering; High-technology industries; L26;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This study examines agency and market signals related to a sample of high-technology firms seeking an initial public offering (IPO). We test a model of the IPO offer process in high-technology firms. Results indicate that certain pre-market and primary market factors affect the offer price received by entrepreneurs and investors, while the secondary market factor did not. Our model may help entrepreneurs position their organization prior to and during the IPO process.
引用
收藏
页码：445 / 463
页数：18
相关论文
共 50 条
  • [1] Testing a model of signals in the IPO offer process
    Williams, David R.
    Duncan, W. Jack
    Ginter, Peter M.
    SMALL BUSINESS ECONOMICS, 2010, 34 (04) : 445 - 463
  • [2] The effectiveness of founder signals and firm performance during the IPO process
    Galloway, Tera L.
    Miller, Douglas R.
    JOURNAL OF RESEARCH IN MARKETING AND ENTREPRENEURSHIP, 2023, 25 (01) : 43 - 62
  • [3] PRAGMATIC IPO MODEL OF MICRO COMMUNICATION PROCESS
    Zhang, Ning
    Liu, Kecheng
    Nakata, Keiichi
    ICISO 2010: PROCEEDINGS OF THE TWELFTH INTERNATIONAL CONFERENCE ON INFORMATICS AND SEMIOTICS IN ORGANISATIONS, 2010, : 149 - 156
  • [4] PCA plans to offer more shares in IPO
    Anon
    Pulp and Paper Week, 2000, 22 (03):
  • [5] Did animal offer relevant model for Bevacizumab testing?
    C Eveno
    S Gaujoux
    G Tobelem
    M Pocard
    British Journal of Cancer, 2008, 99 : 1555 - 1555
  • [6] Did animal offer relevant model for Bevacizumab testing?
    Eveno, C.
    Gaujoux, S.
    Tobelem, G.
    Pocard, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (09) : 1555 - 1556
  • [7] IPO pricing: Growth rates implied in offer prices
    Cogliati G.M.
    Paleari S.
    Vismara S.
    Annals of Finance, 2011, 7 (1) : 53 - 82
  • [8] Concealing and confounding adverse signals: insider wealth-maximizing behavior in the IPO process
    Ang, JS
    Brau, JC
    JOURNAL OF FINANCIAL ECONOMICS, 2003, 67 (01) : 149 - 172
  • [9] Reply: Did animal offer relevant model for bevacizumab testing?
    Bozec, A.
    Sudaka, A.
    Fischel, J. L.
    Brunstein, M. C.
    Grimaldi, M. C.
    Milano, G.
    BRITISH JOURNAL OF CANCER, 2008, 99 (09) : 1556 - 1556
  • [10] Reply: Did animal offer relevant model for bevacizumab testing?
    A Bozec
    A Sudaka
    J L Fischel
    M C Brunstein
    M C Grimaldi
    G Milano
    British Journal of Cancer, 2008, 99 : 1556 - 1556
12345